Patents by Inventor Gary B. Zweiger

Gary B. Zweiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel human cell division cycle proteins
    Publication number: 20030036510
    Abstract: The present invention provides novel human cell division cycle proteins (collectively called HCDC) and polynucleotides which identify and encode HCDC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HCDC. The invention also provides pharmaceutical compositions containing HCDC or antagonists to HCDC, and in the use of these compositions for the treatment of diseases associated with the expression of HCDC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HCDC for the treatment of diseases associated with the expression of HCDC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HCDC or anti-HCDC antibodies which specifically bind to HCDC.
    Type: Application
    Filed: May 28, 2002
    Publication date: February 20, 2003
    Applicant: Incyte Genomics, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Janice Au-Young, Gary B. Zweiger
  • Toxicological response markers
    Patent number: 6403778
    Abstract: The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: June 11, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Mary Jane Cunningham, Gary B. Zweiger, Scott R. Panzer, Jeffrey J. Seilhamer
  • Mammalian toxicological response markers
    Patent number: 6372431
    Abstract: The present invention relates to mammalian nucleic acid and protein molecules comprising a plurality of nucleic acid and protein molecules. The mammalian nucleic acid molecules can be used as hybridizable array elements in a microarray in diagnostic and therapeutic applications including detecting metabolic and toxicological responses, and in monitoring drug mechanism of action. The protein molecules can be used in a pharmaceutical composition. The present invention also relates to methods for screening compounds and therapeutics for metabolic responses indicative of a toxic compound or molecule.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: April 16, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Mary Jane Cunningham, Gary B. Zweiger, Matthew R. Kaser, Scott R. Panzer, Jeffrey J. Seilhamer, Henry Yue, Mariah R. Baughn, Yalda Azimzai, Preeti Lal
  • Monitoring toxicological responses
    Patent number: 6160105
    Abstract: The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: December 12, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Mary Jane Cunningham, Gary B. Zweiger, Scott R. Panzer, Jeffrey J. Seilhamer
  • Markers for peroxisomal proliferators
    Patent number: 6160104
    Abstract: The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: December 12, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Mary Jane Cunningham, Gary B. Zweiger, Scott R. Panzer, Jeffrey J. Seilhamer
  • SnRNP Sm proteins
    Patent number: 6090564
    Abstract: The present invention provides novel human small nuclear ribonucleoprotein (snRNP) Sm proteins (collectively called HSMP) and polynucleotides which identify and encode HSMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSMP. The invention also provides pharmaceutical compositions containing HSMP or antagonists to HSMP, and in the use of these compositions for the treatment of diseases associated with the expression of HSMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSMP for the treatment of diseases associated with the expression of HSMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HSMP or anti-HSMP antibodies which specifically bind to HSMP.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: July 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Olga Bandman, Gary B. Zweiger
  • snRNP Sm proteins
    Patent number: 5955299
    Abstract: The present invention provides novel human small nuclear ribonucleoprotein (snRNP) Sm proteins (collectively called HSMP) and polynucleotides which identify and encode HSMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSMP. The invention also provides pharmaceutical compositions containing HSMP or antagonists to HSMP, and in the use of these compositions for the treatment of diseases associated with the expression of HSMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSMP for the treatment of diseases associated with the expression of HSMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HSMP or anti-HSMP antibodies which specifically bind to HSMP.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Olga Bandman, Gary B. Zweiger